Myotonic dystrophy kinase-related CDC42-binding kinase alpha and beta (MRCKA/MRCKB)

Myotonic dystrophy kinase-related CDC42-binding kinases alpha and beta (MRCKA and MRCKB) are serine/threonine kinases that function as essential downstream effectors of the Rho GTPase CDC42 (UniProt Q5VT25, Q9P2K8). These kinases are pivotal in regulating the actin cytoskeleton by promoting actomyosin contractility, primarily through the phosphorylation of myosin light chain (Heasman & Ridley, 2008). In various malignancies, MRCK signaling is upregulated to facilitate cancer cell invasion and metastatic spread, making them attractive therapeutic targets in squamous cell carcinoma and breast cancer (Unsworth et al., 2019). Small-molecule inhibitors such as BDP-9066 have been developed to target the ATP-binding pocket of these enzymes, effectively blocking their pro-invasive signaling (Cancer Research UK). However, the high structural similarity between MRCK isoforms and the closely related Rho-associated kinases (ROCK1/2) poses a significant challenge for achieving high selectivity. Consequently, many experimental MRCK inhibitors exhibit a profile that includes activity against other kinome members, which can lead to off-target effects and complicate clinical development (Caliper Life Sciences). Monitoring biomarkers like phospho-myosin light chain levels is crucial for assessing the efficacy and selectivity of these therapeutic agents in a clinical setting.

Other names

CDC42BPACDC42BPBMRCK alphaMRCK betaKMPKp190-alphap190-betaMyotonic dystrophy kinase-related CDC42-binding effector kinase alphaMyotonic dystrophy kinase-related CDC42-binding effector kinase beta

ATP-competitive inhibition of the kinase domains of MRCKA and MRCKB, preventing the phosphorylation of myosin light chain (MLC) and other substrates involved in actin-myosin contractility.